Division of Anatomic Pathology, Mayo Clinic, 1st ST SW, Rochester, MN 55905, 200, Rochester, United States.
Sparrow Medical Group, Sparrow Hospital, 1200 E. Michigan ave, Michigan-48912, Lansing, United States.
BMC Nephrol. 2022 Sep 9;23(1):309. doi: 10.1186/s12882-022-02934-0.
Lithium carbonate is commonly used in the treatment of bipolar disorder. A spectrum of side effects is associated with lithium, including nephrogenic diabetes insipidus, renal tubular acidosis, chronic tubulointerstitial nephropathy, and minimal change disease. Although the former three adverse effects are well-known, minimal change disease is relatively rare.
We herein report a case of lithium therapy-induced minimal change disease with concurrent chronic tubulointerstitial nephropathy. A 66-year old man with bipolar disorder treated by lithium for 20 years, presented to the hospital with anasarca and decreased urine output for 4 weeks. The medical history also included hyperlipidemia, hypertension, and benign prostatic hyperplasia. Further laboratory investigation revealed elevated serum lithium (2.17 mmol/L), potassium (6.0 mmol/L), and creatinine levels (2.92 mg/dL), nephrotic range proteinuria, and hypoalbuminemia. Lithium was discontinued and the patient was treated with intravenous fluids. He underwent a kidney biopsy, which showed findings consistent with minimal change disease with concurrent acute tubular injury and chronic tubulointerstitial nephropathy. The patient was subsequently treated with steroids in an outpatient setting. He did not respond to the treatment, and hemodialysis was started.
Based on the previously reported cases and review of literature, occurrence of lithium-associated minimal change nephropathy is rare. Patients with lithium-associated minimal change disease and acute tubular injury usually respond to discontinuation of lithium therapy and/or steroid treatment. In this case, minimal change nephropathy was steroid-resistant and kidney function of the patient reported here did not recover after 6-month follow-up. We postulated the underlying cause to be minimal change disease with chronic tubulointerstitial nephropathy due to long-term lithium use. This case provides an example of a rare side effect of lithium-induced minimal change nephropathy with chronic tubulointerstitial nephropathy in addition to its well-known complication of interstitial nephritis or diabetes insipidus. In our opinion, these patients likely have much worse clinical outcome.
碳酸锂常用于治疗双相情感障碍。锂与一系列副作用相关,包括肾源性尿崩症、肾小管性酸中毒、慢性间质性肾炎和微小病变性肾病。虽然前三种不良反应广为人知,但微小病变性肾病相对少见。
我们在此报告一例锂治疗引起的微小病变性肾病合并慢性间质性肾炎。一名 66 岁男性,因双相情感障碍接受锂治疗 20 年,因水肿和少尿 4 周就诊。病史还包括高脂血症、高血压和良性前列腺增生。进一步实验室检查显示血清锂(2.17mmol/L)、钾(6.0mmol/L)和肌酐水平(2.92mg/dL)升高,肾病范围蛋白尿和低白蛋白血症。停用锂后,患者接受静脉补液治疗。他接受了肾脏活检,结果显示符合微小病变性肾病伴急性肾小管损伤和慢性间质性肾炎。随后,患者在门诊接受了类固醇治疗。但他对此治疗没有反应,开始进行血液透析。
根据既往报道的病例和文献复习,锂相关微小病变性肾病的发生较为罕见。锂相关微小病变性肾病伴急性肾小管损伤的患者通常对停用锂治疗和/或类固醇治疗有反应。在本例中,微小病变性肾病对类固醇耐药,且患者的肾功能在 6 个月随访后未恢复。我们推测潜在病因是长期锂使用导致的微小病变性肾病合并慢性间质性肾炎。该病例提供了一个罕见的锂引起的微小病变性肾病合并慢性间质性肾炎的副作用的例子,此外,它还有其众所周知的并发症,如间质性肾炎或尿崩症。在我们看来,这些患者的临床结局可能更差。